EBioMedicine:英研究发现败血症快速诊断方法

2014-10-31 伊文 生物谷

近日研究发现,英属哥伦比亚大学的研究人员开发了一项新测试,该测试可以帮助医生预测患者是否在一小时内会发生严重的败血症,这样他们就可以立刻开始进行治疗。 败血症是一种由感染引起的综合症,它会导致人体器官衰竭以及每年高达五百万人的死亡。每年全世界约有1800万例败血症患者。 该发现可以减少确认病人是否患有败血症的诊断时间,也会增加他们对疗效的反馈。 “我们发现了一个基因标

近日研究发现,英属哥伦比亚大学的研究人员开发了一项新测试,该测试可以帮助医生预测患者是否在一小时内会发生严重的败血症,这样他们就可以立刻开始进行治疗。

败血症是一种由感染引起的综合症,它会导致人体器官衰竭以及每年高达五百万人的死亡。每年全世界约有1800万例败血症患者。

该发现可以减少确认病人是否患有败血症的诊断时间,也会增加他们对疗效的反馈。

“我们发现了一个基因标记,它与诊断败血症和随后的器官衰竭相关,”Bob Hancock说。“一旦病人去急诊室时我们就可以测试这种基因标记。”一般病人确诊需要24至48小时,但有了这项新的测试,医生马上可以开始治疗病人。

有关基因标记新测试最近发表在 EBioMedicine 杂志上,该测试只需一个小时就可以在败血症发病早期阶段确诊96%的病人。

研究结果也显示对疾病的误解。直到现在败血症依旧被视为一种炎症性疾病,但临床试验中超过30种消炎药对败血症的疗效已经失败了。Hancock和他的同事发现的基因标记与细胞重组免疫抑制剂相关,但是用这种特殊的细胞重组免疫抑制剂治疗炎性败血症却不是一个好方法。

原始出处:

Olga M. Penaa, 1, David G. Hancockb, 1, Ngan H. Lylea, Adam Linderc, James A. Russella, Jianguo Xiaa, Christopher D. Fjella, c, John H. Boydc, Robert E.W. Hancocka, d,An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation.EBioMedicine Available online 7 October 2014


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
    2015-05-07 linagood
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
    2015-04-11 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
    2014-11-09 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
    2015-07-15 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1997064, encodeId=a749199e0642d, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 07 03:57:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917091, encodeId=f99e191e091fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Apr 11 07:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773469, encodeId=32ea1e7346974, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Nov 09 17:57:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858590, encodeId=5f361858590ac, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jul 15 21:57:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753088, encodeId=5bff1e53088e8, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 10 17:57:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709863, encodeId=ab811e0986375, content=<a href='/topic/show?id=2b01916235e' target=_blank style='color:#2F92EE;'>#诊断方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91623, encryptionId=2b01916235e, topicName=诊断方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=977d31798651, createdName=haouestc, createdTime=Sat Apr 11 09:57:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577412, encodeId=59ac15e7412a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606316, encodeId=e2d01606316ab, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 02 01:57:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]

相关资讯

目前SIRS标准不适用于孕产妇败血症的诊断

在英国,败血症在2006–2008年期间是导致母体直接死亡的主要原因。美国围产期严重败血症和败血症导致的相关死亡在1998–2008年期间已增加了一倍。已有研究证明,败血症诊断和治疗的延迟会增加普通人群的死亡率。 而妊娠期生理变化可能是导致败血症诊断延迟的原因。美国胸科医师协会(ACCP)和危重病医学会(SCCM)将败血症的诊断定义为全身炎症反应综合征(SIRS)的继发感染。下列四项标准

Lancet Neurol:依库珠单抗明显改善视神经脊髓炎患者的临床症状

补体与水孔蛋白4(AQP4)IgG自身抗体结合后而激活被认为是造成视神经脊髓炎中枢神经系统炎症和星形胶质细胞损伤的主要机制。来自美国梅奥临床中心的Sean J Pittock等医生评估了依库珠单抗对视神经脊髓炎的治疗作用,结果发表在2013年6月的Lancet Neurology杂志上。该项研究的目的是探索应用依库珠单抗--与补体蛋白C5特异性结合的IgG单克隆抗体--治疗视神经脊髓炎疾病谱疾病的

新型血液测试可预测败血症患者是否死亡

据一项新的研究报告,一种血液测试可以预测败血症患者是否可能会死亡。这种测试所根据的是一种分子特征,即血液中一组特征性的生物化学变化。 败血症是当身体试图对一种感染做出反应时所出现的一种并发症,它是美国排名前10位的致死原因。然而,对这种并发症——它可以影响到任何人——还没有一种标准的治疗,而且没有方法知道这种疾病会变得多么严重。如果医疗护理者能够预测哪些病人可能会死于败血症,那些病人便可立刻由医

北京宣武医院鉴定两例国内首次发现菌种

近日,首都医科大学宣武医院检验科细菌室应用分子生物学技术和质谱技术,鉴定出两例国内首次发现的菌种。 一例是在血流感染(败血症和菌血症)患者血培养中分离出的Rothia aeria。该菌2004年从俄罗斯空间站的水和空气中被首次分离和鉴定,并由此命名,迄今为止很少引起人类感染,全球共6例报道,此例在国内为首例报道。另一例是在尿路感染患者尿液中,分离鉴定出Candida niva

Immunity:重症感染致败血症治疗获新思路

中科院上海生化细胞所王红艳研究组发现,巨噬细胞受细菌感染或细菌脂多糖LPS刺激后,升高血管内皮生长因子受体3(VEGFR-3)的表达。VEGFR-3形成负反馈环路,抑制TLR4-NF-κB介导的炎症反应,降低细菌感染致败血症或内毒素休克的发生。相关论文日前在线发表于《免疫》Immunity杂志。 据介绍,宿主的巨噬细胞通过Toll样受体4(TLR4)识别细菌,并启动免疫应答。但TLR4信号通路是

PLoS One :血凝块能吸收细菌毒素?

在脊椎动物和节肢动物中,血液凝结包括聚集的血小板血栓的形成(细胞凝块)和由凝块的结构蛋白聚合形成的细胞外纤维状凝块,即哺乳动物中的纤维蛋白、甲壳类动物中的血浆脂蛋白和马蹄蟹(Limulus polyphemus)中的凝固素。这些凝块的功能是止血,另外,细胞外凝块还通过提供一种消极的抗菌障碍和微生物截留装置,发挥先天免疫系统的作用,直接作用于皮肤的伤口部位。来自美国加利福尼亚大学(